Botulin Toxin Use in Rosacea and Facial Flushing Treatment

  • Jacopo Scala G. Marconi University, Rome, Italy
  • Aleksandra Vojvodic Department of Dermatology and Venereology, Military Medical Academy, Belgrade, Serbia
  • Petar Vojvodic Clinic for Psychiatric Disorders “Dr. Laza Lazarevic”, Belgrade, Serbia
  • Tatjana Vlaskovic-Jovicevic Clinic for Psychiatric Disorders “Dr. Laza Lazarevic”, Belgrade, Serbia
  • Zorica Peric-Hajzler Military Medical Academy, Belgrade, Serbia
  • Dusica Matovic Military Medical Academy, Belgrade, Serbia
  • Sanja Dimitrijevic Department of Gynecology, Military Medical Academy, Belgrade, Serbia
  • Jovana Vojvodic Clinic for Psychiatric Disorders “Dr. Laza Lazarevic”, Belgrade, Serbia
  • Goran Sijan Clinic for Plastic Surgery and Burns, Military Medical Academy, Belgrade, Serbia
  • Nenad Stepic Chief of Clinic for Plastic Surgery and Burns, Military Medical Academy, Belgrade, Serbia
  • Uwe Wollina Department of Dermatology and Allergology, Städtisches Klinikum Dresden, Dresden, Germany
  • Michael Tirant G. Marconi University, Rome, Italy
  • Van Thuong Nguyen Vietnam National Hospital of Dermatology and Venereology, Hanoi, Vietnam
  • Masssimo Fioranelli Department of Nuclear Physics, sub-nuclear and radiation, G. Marconi University, Rome, Italy
  • Torello Lotti University of Rome G. Marconi, Rome, Italia
Keywords: botulin toxin, rosacea

Abstract

Botulinum toxin (BTX) is a neurotoxin derived from the Clostridium botulinum bacterium that inhibits the release of acetylcholine at the neuromuscular junction level whose effects has been used for many years to treat a variety of muscular/neuromuscular conditions and more recently also for cosmetic use.

BTX has experimented in some dermatological conditions, which include Rosacea and facial flushing treatment with good results. The complex mechanism underlying those results is not completely understood but was proposed a release inhibition of acetylcholine from peripheral autonomic nerves of the cutaneous vasodilatory system combined with the blockade substance P and calcitonin gene-related peptide (CGRP) thus modulating blood vessel dilatation.

We analysed the published data on BTX off label applications rosacea and flushing retrieved from PubMed.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

Author Biography

Torello Lotti, University of Rome G. Marconi, Rome, Italia

Prof. Lotti is Full Professor of the Dermatology and Venereology at University of Studies Guglielmo Marconi, Rome, Italy. He is Honorary Professor of Dermatology - China Medical University Shenyang (2011), Lecturer at the New York Academy of Sciences "Howard Fox Memorial Lecture" (14 March 2012 - New York, NY – USA), and Chair, Executive Scientific Committee Vitiligo Research Foundation, New York , NY , USA. He is President of the World Health Academy, Dermatology since 2013. He has been Full Professor of the Dermatology and Venereology Division at University of Florence School of Medicine, Florence, Italy, from 2006 to 2010. He is Visiting Professor in six International Universities worldwide, and Key Note Lecturer in several international dermatology Societies. His activities in serving Dermatology have been numerous: President of the Italian Society of Dermatology and Venereology (SIDeMaST , 2009-2010) and President of the International Society of Dermatology ( ISD, 2009-2010), President of the European Society for Cosmetic and Aesthetic Dermatology (2003-2004), Editor in Chief of the Journal of the European Academy of Dermatology and Venereology (1992-2002) , Editor "Therapeutic Hotline"- Dermatologic Therapy (2007-)and served as Editor in Chief of the Giornale Italiano di Dermatologia in the period of presidency of the Societa' Italiana di Dermatologia (2009-2010). He has been President of numerous international congresses and is currently Editor in Chief of the Giornale Italiano di Dermatologia e Venereologia ( 2010-2020 ). He is Ordinary Member of the main Scientific Societies worldwide (EADV, SIDEV , ESDR , ISD, AAD, SID) and Honorary Member of several Scientific Societies of the Dermatology field. Moreover, he is a Scientific reviewer of ten sectorial journals, among which are the British Journal of Dermatology, Journal of Investigative Dermatology, Journal of the American Academy of Dermatology , Dermatologic Therapy. He has authored 1054 scientific publications (393 peer reviewed articles, 288 books chapters e 365 abstracts). For more information, see www.torellolotti.it

References

Blasi J, Chapman ER, Link E, et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature. 1993; 365(6442):160-163. https://doi.org/10.1038/365160a0 PMid:8103915

França K, Kumar A, Fioranelli M, Lotti T, Tirant M, Roccia MG. The history of Botulinum toxin: from poison to beauty. Wien Med Wochenschr. 2017; 167(1):46-48. https://doi.org/10.1007/s10354-017-0553-7 PMid:28299552

França K, Castillo D, Lotti T.- Non-cosmetic dermatological use of botulinum neurotoxin. Dermatol Ther. 2017; 30(4). https://doi.org/10.1111/dth.12495 PMid:28425626

Guida S, Farnetani F, Nisticò SP, Giorgio Mariarosaria C, Babino G, Giovanni Pellacani G, Fulgione E. New trends in botulinum toxin use in dermatology. Dermatol Pract Concept. 2018; 8(4):277-282. https://doi.org/10.5826/dpc.0804a05 PMid:30479855 PMCid:PMC6246063

Kim YS, Hong ES, Kim HS. Botulinum Toxin in the Field of Dermatology: Novel Indications. Toxins (Basel). 2017; 9(12):E403. https://doi.org/10.3390/toxins9120403 PMid:29258169 PMCid:PMC5744123

Schlessinger J, Gilbert E, Cohen JL, Kaufman J. New Uses of AbobotulinumtoxinA in Aesthetics.Aesthet Surg J. 2017; 37(1):S45-S58. https://doi.org/10.1093/asj/sjx005 PMid:28388720 PMCid:PMC5434494

Abokwidir M, Feldman SR. Rosacea management. Skin Append- age Disord. 2016; 2(1-2):26-34. https://doi.org/10.1159/000446215 PMid:27843919 PMCid:PMC5096126

Weinkle AP, Doktor V, Emer J. Update on the management of rosacea. Clin Cosmet Investig Dermatol. 2015; 8:159-177. https://doi.org/10.1097/PSN.0000000000000111 PMCid:PMC4396587

Bloom BS, Payongayong L, Mourin A, Goldberg DJ. Impact of intradermal abobotulinumtoxinA on facial erythema of rosacea. Dermatol Surg. 2015; 41(1):S9-16. https://doi.org/10.1097/DSS.0000000000000277 PMid:25548852

Geddoa, E.; Matar, H.E.; Paes, T.R. The use of botulinum toxin-a in the management of neck and anterior chest wall flushing: Pilot study. Int. J. Dermatol. 2013; 52:1547-1550. https://doi.org/10.1111/ijd.12200 PMid:23968244

Odo ME, Odo LM, Farias RV, Primavera RA, Leao L, Cuce LC, Juliano Y. Botulinum toxin for the treatment of menopausal hot flushes: A pilot study. Dermatol. Surg. 2011; 37:1579-1583. https://doi.org/10.1111/j.1524-4725.2011.02109.x PMid:21790852

Eshghi G, Khezrian L, Alirezaei P. Botulinumtoxin A in treatment of facial flushing. Acta Med Iran. 2016; 54(7):454-457.

Dayan SH, Pritzker RN, Arkins JP. A new treatment regimen for rosacea: onabotulinumtoxinA. J Drugs Dermatol. 2012; 11(12):e76-e79.

Park KY, Hyun MY, Jeong SY, Kim BJ, Kim MN, Hong CK. Botulinum toxin for the treatment of refractory erythema and flushing of rosacea. Dermatology. 2015; 230(4):299-301. https://doi.org/10.1159/000368773 PMid:25765295

Clatici VG, Satolli F, Tatu AL, Voicu C, Draganita AMV, LottiT.Butterfly Effect - the Concept and theImplications in Dermatology, Acne, andRosacea. Maedica (Buchar). 2018; 13(2):89-94.

Kellogg Jr DL. In vivo mechanisms of cutaneous vasodilation and vasoconstriction in humans during thermoregulatory challenges. J. Appl. Phys. 2006; 100:1709-1718. https://doi.org/10.1152/japplphysiol.01071.2005 PMid:16614368

Kellogg Jr DL, Pergola PE, Piest KL, Kosiba WA, Crandall M, Johnson JM. Cutaneous active vasodilation in humans is mediated by cholinergic nerve cotransmission. Circ. Res. 1995; 77:1222-1228. https://doi.org/10.1161/01.RES.77.6.1222 PMid:7586235

Carmichael NM, Dostrovsky JO, Charlton MP. Peptide-mediated transdermal delivery of botulinum neurotoxin type A reduces neurogenic inflammation in the skin. PAIN®. 2010; 149(2):316-24. https://doi.org/10.1016/j.pain.2010.02.024 PMid:20223589

Steinhoff M, Ständer S, Seeliger S, Ansel JC, Schmelz M, Luger T. Modern aspects of cutaneous neurogenic inflammation. Archives of dermatology. 2003; 139(11):1479-88. https://doi.org/10.1001/archderm.139.11.1479 PMid:14623709

Ansel JC, Kaynard AH, Armstrong CA, Olerud J, Bunnett N, Payan D. Skin-nervous system interactions. J. Investig. Dermatol. 1996; 106:198-204. https://doi.org/10.1111/1523-1747.ep12330326 PMid:8592075

Published
2019-08-30
How to Cite
1.
Scala J, Vojvodic A, Vojvodic P, Vlaskovic-Jovicevic T, Peric-Hajzler Z, Matovic D, Dimitrijevic S, Vojvodic J, Sijan G, Stepic N, Wollina U, Tirant M, Nguyen VT, Fioranelli M, Lotti T. Botulin Toxin Use in Rosacea and Facial Flushing Treatment. Open Access Maced J Med Sci [Internet]. 2019Aug.30 [cited 2020Oct.26];7(18):2985-7. Available from: https://www.id-press.eu/mjms/article/view/3678

Most read articles by the same author(s)

1 2 3 > >>